These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 34460318)

  • 1. Apolipoprotein E and Alzheimer's Disease: Findings, Hypotheses, and Potential Mechanisms.
    Koutsodendris N; Nelson MR; Rao A; Huang Y
    Annu Rev Pathol; 2022 Jan; 17():73-99. PubMed ID: 34460318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of ApoE4 on the Pathogenesis in Alzheimer's Disease and the Potential Therapeutic Approaches.
    Sun YY; Wang Z; Huang HC
    Cell Mol Neurobiol; 2023 Oct; 43(7):3115-3136. PubMed ID: 37227619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer's disease.
    Raulin AC; Doss SV; Heckman MG; Craver EC; Li Z; Ikezu TC; Sekiya H; Liu CC; Martens YA; Rosenberg CL; Kuchenbecker LA; DeTure M; Reichard RR; Nguyen AT; Constantopoulos E; Larsen RA; Kounaves EK; Murray ME; Dickson DW; Petersen RC; Bu G; Kanekiyo T
    Acta Neuropathol Commun; 2024 Feb; 12(1):25. PubMed ID: 38336940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis.
    Uddin MS; Kabir MT; Al Mamun A; Abdel-Daim MM; Barreto GE; Ashraf GM
    Mol Neurobiol; 2019 Apr; 56(4):2450-2465. PubMed ID: 30032423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice.
    Kunzler J; Youmans KL; Yu C; Ladu MJ; Tai LM
    Neurosci Lett; 2014 Feb; 560():131-6. PubMed ID: 24368217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOE4 is a Risk Factor and Potential Therapeutic Target for Alzheimer's Disease.
    Ayyubova G
    CNS Neurol Disord Drug Targets; 2024; 23(3):342-352. PubMed ID: 36872358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease.
    Li Y; Macyczko JR; Liu CC; Bu G
    Neurobiol Aging; 2022 Jul; 115():20-28. PubMed ID: 35453035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer's Disease.
    Kloske CM; Wilcock DM
    Front Immunol; 2020; 11():754. PubMed ID: 32425941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease.
    Williams T; Borchelt DR; Chakrabarty P
    Mol Neurodegener; 2020 Jan; 15(1):8. PubMed ID: 32005122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.
    Hartman RE; Laurer H; Longhi L; Bales KR; Paul SM; McIntosh TK; Holtzman DM
    J Neurosci; 2002 Dec; 22(23):10083-7. PubMed ID: 12451108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation.
    Buttini M; Yu GQ; Shockley K; Huang Y; Jones B; Masliah E; Mallory M; Yeo T; Longo FM; Mucke L
    J Neurosci; 2002 Dec; 22(24):10539-48. PubMed ID: 12486146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.
    Refolo LM; Fillit HM
    J Mol Neurosci; 2004; 23(3):151-5. PubMed ID: 15181243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular Dysfunction Is Central to Alzheimer's Disease Pathogenesis in APOE e4 Carriers.
    McCorkindale AN; Mundell HD; Guennewig B; Sutherland GT
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoe4 and Alzheimer's Disease Pathogenesis-Mitochondrial Deregulation and Targeted Therapeutic Strategies.
    Pires M; Rego AC
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614219
    [No Abstract]   [Full Text] [Related]  

  • 15. Connections between ApoE, sleep, and Aβ and tau pathologies in Alzheimer's disease.
    Sadleir KR; Vassar R
    J Clin Invest; 2023 Jul; 133(14):. PubMed ID: 37463448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk.
    Huang YA; Zhou B; Nabet AM; Wernig M; Südhof TC
    J Neurosci; 2019 Sep; 39(37):7408-7427. PubMed ID: 31331998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer's disease.
    Najm R; Jones EA; Huang Y
    Mol Neurodegener; 2019 Jun; 14(1):24. PubMed ID: 31186040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-Expression of Glia Maturation Factor and Apolipoprotein E4 in Alzheimer's Disease Brain.
    Thangavel R; Bhagavan SM; Ramaswamy SB; Surpur S; Govindarajan R; Kempuraj D; Zaheer S; Raikwar S; Ahmed ME; Selvakumar GP; Iyer SS; Zaheer A
    J Alzheimers Dis; 2018; 61(2):553-560. PubMed ID: 29172001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E intersects with amyloid-β within neurons.
    Konings SC; Nyberg E; Martinsson I; Torres-Garcia L; Klementieva O; Guimas Almeida C; Gouras GK
    Life Sci Alliance; 2023 Aug; 6(8):. PubMed ID: 37290814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOE Peripheral and Brain Impact: APOE4 Carriers Accelerate Their Alzheimer Continuum and Have a High Risk of Suicide in PM
    Calderón-Garcidueñas L; Hernández-Luna J; Aiello-Mora M; Brito-Aguilar R; Evelson PA; Villarreal-Ríos R; Torres-Jardón R; Ayala A; Mukherjee PS
    Biomolecules; 2023 May; 13(6):. PubMed ID: 37371506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.